These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27606697)

  • 1. Extended anti-HER2 therapy in early breast cancer: longer beats shorter?
    Refae S; Pistilli B; Delaloge S
    Curr Opin Oncol; 2016 Nov; 28(6):469-475. PubMed ID: 27606697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalating and de-escalating treatment in HER2-positive early breast cancer.
    Joensuu H
    Cancer Treat Rev; 2017 Jan; 52():1-11. PubMed ID: 27866067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
    Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
    Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
    Zardavas D; Fouad TM; Piccart M
    Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
    Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual HER2-Targeting in the Adjuvant Setting: Where We Have Been and Where We Are Going.
    Copeland AC; Anders CK
    Oncology (Williston Park); 2018 Oct; 32(10):483-7. PubMed ID: 30334236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trastuzumab: a 10-year overview of its benefit.
    Lambertini M; Pondé NF; Solinas C; de Azambuja E
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):61-74. PubMed ID: 27883296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V; Dieci MV; Frassoldati A; Maiorana A; Ficarra G; Bettelli S; Tagliafico E; Bicciato S; Generali DG; Cagossi K; Bisagni G; Sarti S; Musolino A; Ellis C; Crescenzo R; Conte P
    Oncologist; 2015 Sep; 20(9):1001-10. PubMed ID: 26245675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
    Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
    Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
    Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards personalized treatment for early stage HER2-positive breast cancer.
    Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
    Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials.
    Gyawali B; Niraula S
    Cancer Treat Rev; 2017 Nov; 60():18-23. PubMed ID: 28863313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.